MeiraGTx Holdings plc is a clinical-stage company developing genetic medicine treatments using adeno-associated virus vectors and other approaches targeting conditions in ophthalmology, neurology, and other therapeutic areas. The company's pipeline includes programs in various stages of development, from early-stage research through Phase 2 clinical trials, alongside technology platforms for peptide delivery and cell therapies. MeiraGTx has partnerships with major pharmaceutical companies including Johnson & Johnson for inherited retinal diseases and Hologen for neurological conditions and metabolic disorders.
1Y: 9.49 (+4.5%) · range 6.99–14.97
entry readiness 82 · STRONG SETUP · exit proximity 0
Value area 9.02–12.90 · 89% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -8.79% | +4.04% | mature |
| 40d | -34.10% | +4.04% | mature |